🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

A Global Health Concern

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million instances annually. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are increasingly worried about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This drug, which is additionally indicated for UTIs, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This approval marks a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Testing Data and Global Access

Based on data released by a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The research involved nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous developing nations.

Doctors on the front lines have expressed hope. The availability of a one-pill regimen like this is seen as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea worldwide.